following a full submission:
fluticasone furoate/vilanterol (Relvar Ellipta®) is accepted for restricted use within NHS Scotland.
Indication under review: symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.
SMC restriction: in patients with severe COPD (FEV1 <50% predicted normal).
In a comparative, 12-week study there was no statistically significant difference between fluticasone furoate/vilanterol 92/22 micrograms and another inhaled corticosteroid/long acting beta agonist combination inhaler for change from baseline trough in 24-hour weighted-mean FEV1.
Fluticasone furoate/vilanterol is also licensed for the treatment of asthma. SMC is due to issue advice for this indication in June 2014.
Download detailed advice244KB (PDF)
Medicine details
- Medicine name:
- fluticasone furoate/vilanterol (Relvar Ellipta)
- SMC ID:
- 953/14
- Indication:
- Symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 April 2014